Nile Initiates Phase I Heart Failure Study
Posted on: Thursday, 7 February 2008, 09:01 CST
Nile Therapeutics has dosed first patient in its Phase Ib, multi-center, open-label, ascending dose clinical study of the company's CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.
The primary objectives of the study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Safety assessments include measurement of blood pressure, heart rate, serum potassium and kidney function as calculated by glomerular filtration rate (GFR). Clinical assessments include urine flow rate, sodium excretion rate and plasma cGMP, a secondary messenger of the target receptor. The trial is expected to enroll up to approximately 35 patients.
Peter Strumph, CEO of Nile, said: "This trial provides us our first opportunity to assess the drug's activity in heart failure patients, and to further build on our understanding of the molecule's mechanism of action."
Source: Datamonitor
Related Articles
- American Heart Association Late-Breaking Clinical Trial Report: Tailoring Drug Dose to Heart Failure Patients' Response More Effective
- 1 In 4 Hospitalized Heart Failure Patients With Medicare Back In Hospital Within A Month
- Hospital Care for Heart Attack, Heart Failure Patients Varies Across Nation
- Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
- Clinical Data Show CVRx(R) Rheos(R) Therapy Improved Heart Structure and Function in Early-Stage Heart Failure Patients
- Examine Successful Management of Heart Failure Patients: The Multidisciplinary Approach to Reducing Readmissions
- St. Jude Medical Announces Japanese Approval of CRT-D Products to Treat Heart Failure Patients
- Data From Two Published Studies Show Short- and Long- Term Benefits of CHF Solutions' Aquapheresis(TM) Therapy in Treating Heart Failure Patients With Fluid Overload
- Research Suggests That Cardiac Marker NT-proBNP is a Better Predictor for Mortality Than BNP in Heart Failure Patients With Reduced Kidney Function
- Role of Cholesterol Lowering Drugs in Heart Failure Patients Evaluated in Yale Medical Center's Heart Study
 |
 |
User Comments (0)
RSS Feeds